American Bio Medica Corporation (ABMC)

Market Cap	4.81K
Revenue (ttm)	726.00K
Net Income (ttm)	850.00K
Shares Out	48.10M
EPS (ttm)	0.02
PE Ratio	0.01
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	5,127
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0001 - 0.0020
Beta	27.77
RSI	90.24
Earnings Date	n/a

About American Bio Medica

American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detec...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 20
• Stock Exchange: OTCMKTS
• Ticker Symbol: ABMC

Financial Performance

In 2022, American Bio Medica's revenue was $913,000, a decrease of -58.84% compared to the previous year's $2.22 million. Losses were -$1.41 million, 204.5% more than in 2021.